Women's health care committee, Japan Society of Obstetrics and Gynecology: Annual report-2024.

The Women's Health Care Committee was established in 2010 to improve the health of women. In the current academic year, this committee established seven subcommittees aimed at understanding diseases related to various age groups of women, including adolescence, sexual maturity, and menopause, and promoting research to improve the quality of life. Additionally, socially significant research has focused on infections, particularly resistant bacteria.

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients - An Open-Label Phase 2 Study.

Background: Selexipag, an oral prostacyclin (PGI) receptor agonist, is approved for adult patients with pulmonary arterial hypertension (PAH). This study evaluated the efficacy and safety of selexipag for Japanese pediatric patients with PAH.

Methods And Results: The study enrolled 6 patients who received selexipag twice daily at an individualized dose based on body weight; maintenance doses were determined for each patient by 12 weeks after starting administration.

Prediction of Aneurysm Sac Shrinkage After Endovascular Aortic Repair Using Machine Learning-Based Decision Tree Analysis.

Introduction: A simple risk stratification model to predict aneurysm sac shrinkagein patients undergoing endovascular aortic repair (EVAR) for abdominal aortic aneurysms (AAA) was developed using machine learning-based decision tree analysis.

Methods: One hundred nineteen patients with AAA who underwent elective EVAR at Tokyo Medical University Hospital between November 2013 and July 2019 were included in the study. Predictors of aneurysm sac shrinkage identified in univariable analysis (P < 0.

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.

Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.

Assisted reproductive technology in Japan: A summary report for 2022 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.

Purpose: This descriptive analysis evaluated the 2022 assisted reproductive technology (ART) data collected by the Japan Society of Obstetrics and Gynecology registry.

Methods And Results: In 2022 (cutoff date 30 November 2023), 634 of 635 registered ART facilities participated; 602 implemented ART treatment, with 543 630 registered cycles and 77 206 neonates (9.1% and 10.